Affordable Access

Neoadjuvant therapy for cervical cancer.

Authors
  • Kuehnle, H
  • Meerpohl, H G
  • Eiermann, W
  • Achterrath, W
Type
Published Article
Journal
Seminars in Oncology
Publisher
Elsevier - WB Saunders
Publication Date
Feb 01, 1992
Volume
19
Issue
1 Suppl 2
Pages
94–98
Identifiers
PMID: 1411633
Source
Medline
License
Unknown

Abstract

The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades. Our research work concerning adjuvant chemotherapy for the early stages induced a pilot study with untreated patients in advanced stages. Patients were treated with carboplatin 300 mg/m2 plus ifosfamide 5 g/m2 on day 1. In cases of remission or no change, the therapy was repeated after 4 weeks. A third course was given only after further remission. After chemotherapy, patients were treated with surgery or radiotherapy according to feasibility. A total of 34 patients were admitted to this study. Thirty-two patients with 88 chemotherapy courses were evaluable for response and toxicity. Nineteen patients achieved remission; three achieved complete remission. The most common toxic effects were myelosuppression with grade four leukopenia (28%) and thrombocytopenia (13%). Alopecia (60%) was the main nonhematologic toxicity. In conclusion, we suggest that this regimen is as effective as other platin-containing regimens for squamous cell carcinoma of the cervix uteri, but its hematologic toxicity precludes its recommendation in an adjuvant setting.

Report this publication

Statistics

Seen <100 times